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Objectives: In 2006, Conditional Marketing Authorisation (MA) was implemented 
by the European Medicines Agency (EMA) to ensure early access to innovative medi-
cations for patients in Europe. The objective of this study is to compare the health 
technology assessment (HTA) process in France, England, and Germany for medi-
cines having received a conditional approval over the past 9 years MethOds: The 
present study concerned all medicines having been approved with a conditional 
MA. The HTA assessments performed by three national bodies, IQWiG, NICE and 
HAS, were compared for these products. Results: Of the 19 medicines for which 
a conditional MA was requested, 17 have received an approval of this type. Three 
of these approved medicines have not yet been assessed by any of the three HTA 
bodies, or are currently undergoing assessment. Four medicines have undergone 
HTA assessment by all three agencies. An additional 9 medicines have been assessed 
in two of the three countries (4 by both HAS and NICE and 5 by both HAS and 
IQWiG). Whereas all products assessed by HAS received a favourable opinion for 
reimbursement, NICE and IQWiG are more restrictive in their recommendations. 
Indeed, only 1/8 medicines assessed by NICE received a favourable recommendation 
and 5/ 9 by IQWiG. Of note, a specific regulatory framework has been implemented in 
Germany by which IQWiG considers all orphan products approved by EMA to provide 
an added medical benefit. This disposition concerned 4 of the 5 products having 
received a favourable opinion in Germany. cOnclusiOns: The HTA assessments 
by HAS, IQWiG and NICE of medicines having received a conditional approval are 
heterogeneous and lead to differing reimbursement statuses. Different criteria are 
taken into consideration, including the relevance of the comparator, the clinical 
trial design and endpoints as well as the relevant target population and health 
economic assessment.
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Objectives: In 2014 the Catalan Health Service (CatSalut) published a guide (GAEIP) 
which describes the methodology for the economic evaluation of medicines in 
Catalonia. Now the objective is to design the operational aspects to introduce both 
the economic evaluations (EE) and budget impact analyses (BIA) of medicines in the 
three Health Technology Assessment (HTA) programmes of CatSalut. MethOds: 
The Commission for Economic Evaluation and Budget Impact (CAEIP) of CatSalut 
led the project that: 1) reviewed the processes undertaken by other countries that 
use EE/BIA of medicines; 2) ran focus groups with representatives of each of the 
three HTA programmes: primary and community care (PHF-APC), hospital medicines 
administered in ambulatory care (PHF-MHDA), and orphan medicines (PASFTAC); 
3) validated the proposal through pilots in each programme. Results: The pro-
ject delivered a general framework to implement the EE and BIA in the current 
processes of each of the three HTA programmes, allowing them to fit it into their 
timings and particular needs. According to this proposal, companies will submit 
their EE and BIAs of medicines in a similar way to what they currently do in single 
technology appraisals. The HTA programmes will assess the quality of the submitted 
information, and may ask for additional analyses when required. To date, the pilot 
on the therapeutic area of oncology has been completed (PHF-MHDA) whilst the 
other two are still ongoing. CAEIP also developed a set of formularies to be used by 
the companies when submitting the required information. Finally, the project was 
informative, as it highlighted the size the resources needed to implement this new 
process within the HTA programmes. cOnclusiOns: CatSalut continues with the 
deployment of EE and BIA as it believes both to be valuable when issuing recom-
mendations on the use and the therapeutic positioning of medicines within the 
Catalan health system.
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Objectives: ED processes between manufacturers, Regulators and HTAs was 
developed to improve quality of evidence and patient access to new medicines. 
SEED is a pilot project financed by the EC involving 14 EU HTAs. Sanofi engaged in 
HTA ED with or without Regulators in four different occasions. This is an overview 
of lessons learnt and suggestions for future improvements. MethOds: In order 
to collect quantitative and qualitative information on the execution of the pilots 
and to evaluate their impact on evidence generation, Sanofi conducted a cross 
sectional analysis amongst all departments involved in the four EDs through: - An 
ad hoc questionnaire probing quality of process, feedback and consensus across 
agencies - Candid meetings to refine response interpretation. Results: Approval 
requests, Briefing Book (BB) completions and clarifications were straightforward, 
although coordination was sometimes lacking. Process timelines seemed appro-
priate, nevertheless great variability in Sanofi’s efforts was observed depending on 
the therapeutic area and the type of advice sought. Teams were generally satisfied 
with the meetings, with good contributions from stakeholders and topics properly 
addressed. However, relevant items not reported in the BB could not be raised dur-
ing the discussion, not all attendees were involved in national negotiations and 
patients were not consistently represented. The quality of the feedback before, 
during and after the meeting was satisfactory. Yet, seeking consensus across HTAs 
was not observed, nor the final report always consistent with meeting discus-
sions. cOnclusiOns: Sanofi satisfaction about the ED experience was gener-
ally high, allowing to pressure test evidence development plans and scenarios, 
while garnering feedback on critical items from multiple countries. In order to 
truly improve evidence generation, some flexibility during the meeting should be 
allowed and consensus of opinion/advice achieved. All teams agreed on consulting 
in similar EDs in the future.
identified four products: trastuzumab emtansine, sofosbuvir, dolutegravir and 
riociguat. All had been assessed by CEESP and SMC; only one NICE assessment 
was published (sofosbuvir). For all products, except sofosbuvir, the type of model 
was different between agencies. All the published CEESP opinions reviewed cost-
effectiveness (CEA) and cost-utility analyses (CUA) whereas SMC and NICE only 
published CUA. Comparators and perspectives used were also different. For tras-
tuzumab emtansine, the Incremental Cost Effectiveness Ratio (ICER) published 
by SMC was 26.5% lower than the one published by CEESP. According to SMC 
guidance, riociguat and dolutegravir were dominant versus comparators, whereas 
CEESP published ICERs of 108 876 € /QALY and 16 526 € /QALY respectively. For 
sofosbuvir, most UK ICERs were higher than French ones. cOnclusiOns: Results 
confirm differences in recommendations and methodological requirements 
between the three agencies. Comparator heterogeneity due to different local 
practices appears to be a key factor leading to discrepancies in ICERs and cost-
effectiveness assessment. ICERs were higher in France than in the UK, possibly 
due to absence of established thresholds and no explicit impact on reimbursement 
decision.
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Objectives: Persistently stubborn infant mortality rates across the world have 
prompted the use of mobile technologies to assist in vaccine adherence. This sys-
tematic review attempts to assess the efficacy of a mobile phone technology in 
delivering timely infant immunization reminders and ensuring compliance and 
follow-up rates. MethOds: Studies were identified based on pre-specified criteria 
from two journals (BMJ and Lancet) and three databases (PUBMED, Google Scholar 
and Cochrane). The articles were screened for PICO (Population, Intervention, 
Control and Outcome) parameters and subsequently shortlisted when they included 
the desired target population, namely infants and mothers and used the methodol-
ogy of Randomized Controlled Trials (RCTs). Biases on account of dropouts, selection 
and blinding methods were taken into consideration. Risk ratios were analyzed for 
the review using a forest plot and bias graphs. Results: A total of 71 studies were 
identified based on results of which 3 duplicates were excluded. Of the 68, 25 were 
screened for PICO parameters and eventually of the 22 full-text articles reviewed. 
6 were RCTs and qualified as relevant for the Health Technology Assessment. The 
studies, published between 1996 and 2014, recorded the participation of 5999 infants 
and mothers across 5 clinic based interventions and 1 province-based intervention. 
A risk ratio of 0.67 indicates that the mobile-based intervention is 45% more effective 
than the control, suggesting the former to be a crucial measure to improve outcome 
measures such as timeliness of immunization and increased infant vaccine aware-
ness. cOnclusiOns: Our analysis suggests that the use of mobile technologies 
could marginally improve compliance in the intervention groups, even if they do not 
affect the overall immunization rates. The evidence also shows that incorporating 
this scheme into an existing health system requires a small investment that could 
potentially result in sizeable gains in reducing infant and neonatal mortality and 
morbidity, particularly in resource-limited settings.
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Objectives: There has been significant discussion on implementing a single Health 
Technology Assessment (HTA) process in Europe, in part because of the high level of 
variability among existing agencies. Agencies often disagree on the reimbursement 
decisions and on the economic and clinical conclusions. While disagreement on eco-
nomic evaluations and reimbursement decisions can be explained by different agency 
remits and healthcare budgets, the driving factors of and justifications for clinical var-
iability are currently unknown. This analysis examines drivers of clinical variability, 
specifically the clinical comparator, and uses case studies to explore instances where 
different comparators were used. MethOds: 198 reviews from NICE, SMC, PBAC, HAS 
and CADTH’s Common Drug Review were analyzed. Therapeutics were matched on 
indication, and the most recent review since 2007 for each agency was included if it 
was also reviewed by NICE. Agreement with NICE on the clinical comparator(s) used 
and on clinical evaluations were evaluated. Results: Agreement with NICE on the 
clinical comparator(s) ranged from 40% to 65%. Other agencies agreed with NICE’s 
clinical evaluations slightly more often when they also agreed on the comparator (54% 
vs. 45%); however, this trend was not statistically significant (p= .31). Case study evalu-
ations indicated that differences in country standards of care and agencies’ willing-
ness to accept comparators used in the clinical trials were common concerns in cases 
of comparator disagreement. cOnclusiOns: While there appears to be variability 
between NICE and the other agencies in comparator(s) evaluated, this does not appear 
to be a driving factor in clinical variability. Where differences in comparator(s) exist, 
a main theme identified was the differences in standards of care between countries. 
If agencies evaluate different comparators because of local standards of care, differ-
ent agencies would have to be willing to accept comparators not in line with their 
standard practices in order to implement a pan-European system.
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of the national assessment. cOnclusiOns: This report indicates that manufactur-
ers can expect delays in the publication of national IPTs. Furthermore, manufactur-
ers can still expect their products to be evaluated at a regional level, regardless of 
undergoing the national procedure. Regional decisions may still be taking place due 
to the prolonged time taken for the publication of these national reports.
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Objectives: Manufacturers of products selected for NICE appraisal are able to 
choose whether or not to present submissions. Choosing not to submit results 
in termination of the appraisal, with words to this effect recorded on the NICE 
website. As the reimbursement landscape in Scotland can differ to that in England 
and Wales, a comparison was made between the SMC submission status and 
the non-submission status recorded by NICE. MethOds: This study reviewed 
previous NICE appraisals and examined trends in technologies and disease areas 
where a decision to not submit to NICE was taken. Single technology apprais-
als (STAs) listed as “Terminated appraisal – non submission” on the NICE web-
site were identified, with terminated appraisals categorised by year and disease 
area. Products that did not submit were entered into the SMC website to see 
whether a submission was made to the SMC. Trends in non-submissions were 
identified. Results: A total of 189 NICE STAs were identified. Of these, twenty 
submissions were recorded as non-submissions. Two of these submissions were 
later replaced by updated technology appraisals (TA147 and TA150). The frequency 
of non-submission varied by year, with five non-submissions recorded in 2013. 
Over half of these terminated submissions were in oncology. A comparison was 
made against submissions to the SMC. Of the twenty non-submissions to NICE 
only six reviews in matching indications were identified for the SMC. Of these four 
submissions were identified as full submissions. cOnclusiOns: The decision 
to not submit to NICE was taken in 10% of STAs identified. Of those matched on 
the SMC website, four full submissions were received by the SMC. Further analy-
sis regarding the implications on reimbursement and patient access differences 
across the UK should be undertaken.
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Objectives: To investigate differences between therapeutic innovative criteria cur-
rently used in France and Italy and their implications for pricing and reimburse-
ment. The French (Haute Autorité de Santé, HAS) and Italian (Agenzia Italiana del 
Farmaco, AIFA) national authorities both evaluate therapeutic innovation of new 
medicines as part of their drug approval process. This comparative analysis exam-
ines criteria used to assess innovation in France (Service Médical Rendu [SMR]; 
Amélioration du Service Médical Rendu [ASMR]) and Italy. MethOds: Peer-reviewed 
literature including French and Italian reports and health technology assessment 
(HTA) websites were searched for publically-available records of new drugs evalu-
ated for therapeutic innovation in France and Italy since 2010. Eighteen drugs on 
the Italian innovative drug list were compared against French SMR and ASMR rank-
ings. Results: The findings of this study show similarities between the decision-
making processes in each country. However, differences exist in the algorithms 
applied to evaluate therapeutic innovation, leading to different outcomes in each 
country. For example, in 2012 ipilimumab was classified as an ‘H’ class drug (only 
fully reimbursed in hospitals) and ranked ‘important’ for innovation in Italy. On the 
other hand, in France, ipilimumab received an ‘important’ SMR score (i.e. 65% level 
of reimbursement) but only an ASMR score ‘IV’ for innovation (minor improvement 
in actual benefit in terms of therapeutic strategy). cOnclusiOns: France and Italy 
currently have complex systems for determining therapeutic innovation to set clini-
cal value and reimbursement rates. Inconsistencies between the countries may lead 
to disparities in access and in pricing and reimbursement of innovative medicines. 
Further clarification of the terminology used in each set of criteria is required in 
both countries. France may benefit from the implementation of a simplified new 
therapeutic index (e.g. Relative Therapeutic Index, new criteria proposed in 2012).
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Objectives: Hospital Based Health Technology Assessment (HB-HTA) became 
increasingly relevant because of its role in ensuring the introduction of evidence-
based technologies and eventually in enhancing better outcomes for end-users. 
The organizational arrangements performed to run such activities are different 
and depend on several factors, even if some common points may be considered as 
minimal basis. The aim of this study is to identify and critically appraise existing 
different organizational models for HB-HTA. MethOds: Data used in this study was 
gathered within European Project AdHopHTA, granted under the 7th Framework 
Research Programme, which is aimed at strengthening the use and impact of HTA 
in hospital settings. A semi-structured interview was developed from the adapta-
tion of the European Foundation for Quality Management Model, in order to inquire 
several aspects characterizing the organizational model. Finally, 7 HB-HTA units 
were involved in the study. Results: Our results show that the organizational 
models depend on a number of contingent variables. Specifically, the combination 
of the level of formalization/specialization and the degree of integration with the 
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Objectives: In France, decree n°2012-1116 passed on 2 October 2012 made it man-
datory for manufacturers of medicines to submit a cost-effectiveness model to the 
Economic and Public Health Assessment Committee (CEESP) when requesting an 
Improvement of Medical Benefit (ASMR) of I-III in their reimbursement submission 
to the Transparency Committee (CT). Our objective was to gauge the impact of this 
decree on the ASMR levels requested by manufacturers. MethOds: We investi-
gated ASMR I-III levels requested before and after the adoption of the decree. All 
CT meeting minutes published by the French National Authority for Health (HAS) 
between January 2012 and March 2015 were reviewed. Four time periods were evalu-
ated: 1. 04/01/2015 – 03/10/2012; 2. 04/10/2012 – 03/10/2013 (the day it took effect); 3. 
04/10/2013 – 01/10/2014; 4. 02/10/2014 – 18/03/2015. Additionally we looked at initial 
submissions for new medicines, assuming these were more susceptible to be influ-
enced by the new decree. If manufacturers increased the number of requests made 
for ASMR I-III in period two and then subsequently decreased them, this would 
suggest they were trying to avoid submitting cost-effectiveness models. Results: 
Over the study period there were 231 ASMR requests of which 83 (35.9%) were for an 
ASMR I-III and 135 (58.4%) for an ASMR IV or V. The proportion of ASMR I-III requests 
for periods one, two, three and four were 19 (40.4%), 16 (27.1%), 29 (35.4%) and 19 
(44.2%) respectively. Of the 83 ASMR I-III requests 47 were initial submissions: 12 
(35.3%) period one; six (18.2%) period two; 17 (35.4%) period three; 12 (52.2%) period 
four. cOnclusiOns: Against the baseline period, total requests for an ASMR I-III 
fell from 40.4% to 27.1% of all requested ASMRs, only to increase in each of the sub-
sequent two periods. A similar pattern holds for initial submissions. These results 
suggest manufacturers didn’t change their behaviour to avoid submitting cost-
effectiveness models.
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Objectives: The health technology assessment (HTA) is used, among other func-
tions, in order to support decision-making on the incorporation of new technologies 
in public health systems. Generally, those decisions are based on criteria such as 
efficacy, effectiveness, safety and cost-effectiveness and, besides that the health 
system context as a whole has also a great influence on reimbursement/invest-
ment on health technologies and such informations are not always explicit or well 
weighted in a systematic way. Thus, this work aims to raise and compare system-
atic HTA tools and its criteria used during the decision-making process on new 
technologies incorporations in different health systems. MethOds: A review was 
conducted, then studies describing systematic methods of HTA on reimbursement/
investment decision-making in public health system were selected and finally a 
descriptive analysis was performed. Results: As HTA systematic tools there were 
found multicriteria decision analysis (MCDA), assessment scoring system and public 
health benefit of medicines (PHB), among others. In addition to efficacy, effective-
ness, safety and cost-effectiveness criteria, some evaluations had also considered 
other elements, namely: epidemiology, disease burden, quality-adjusted life year 
(Qaly), presence of therapeutic alternative, societal value, patient impact, quality of 
the evidence, innovativeness, impacts on equity, ethical consequences, convenience, 
feasibility and acceptability. A major barrier found in multicriteria evaluation was 
the lack of reliable data for all criteria. cOnclusiOns: This study has raised HTA 
experiences in a variety of public systems proving that HTA normally takes multic-
riteria into account. However not all of them are considered multicriteria analysis 
(MCA) because this technique generally supply an explicit relative weighting system 
for the different criteria and not all HTA proceed in this manner. Generally, it was 
noted that the use of multicriteria can contribute to objectiveness, transparency and 
accountability of the process, thus enhancing legitimacy of the political decisions.
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Objectives: In December 2012, the Spanish Government approved publication 
of the Spanish ‘Place in Therapy’ reports (IPTs [Informes de posicionamiento tera-
péutico]) which are used to inform pricing and reimbursement decisions with the 
Ministry of Health. These reports were implemented to create a single national 
assessment and thereby negate the need for regional decision making, and ensur-
ing equal access to therapies throughout Spain. A further aim of IPTs was to ensure 
fast access, with the Spanish Government committing to their publication within 
3 months of European Medicines Agency (EMA) approval. This analysis aimed to 
determine whether IPTs have successfully met their objectives. Can manufacturers 
expect IPT publication within 3 months post-EMA approval and have they success-
fully prevented regional assessments, thereby ensuring equal access throughout 
Spain? MethOds: A retrospective analysis of IPTs from their implementation 
in 2012 to present was carried out by extracting information from the Spanish 
Medicines Agency, from the EMA and from the regional health technology assess-
ment boards. Results: To June 2015, 38 drugs have been assessed via an IPT, two 
of which were assessed for more than one indication. The average time from EMA 
authorisation to IPT publication is 25 months. This is reduced to 14 months when 
only drugs marketed after December 2012 are considered. Seventy percent of the 
drugs evaluated via the IPT procedure have also been evaluated via a regional 
assessment, of which, 68% were evaluated at a regional level prior to the publication 
